#1 Clinical Trials Search in Europe

Munc-T3

A groundbreaking clinical trial is underway to evaluate the safety and effectiveness of a novel gene therapy approach for treating Familial Hemophagocytic Lymphohistiocytosis Type 3 (FHL 3). This study focuses on using modified stem cells and T-cells to potentially replace traditional transplant methods, offering hope for improved outcomes and reduced complications for patients with this rare genetic disorder.

Table of Contents

What is MUNC-T3?

MUNC-T3 is an innovative gene therapy treatment being studied for patients with a rare genetic condition called Familial Hemophagocytic Lymphohistiocytosis Type 3 (FHL 3)[1]. This therapy is part of a clinical trial that aims to provide a new treatment option for patients who may not respond well to current treatments or who have experienced complications from other therapies.

Target Condition: Familial Hemophagocytic Lymphohistiocytosis Type 3 (FHL 3)

Familial Hemophagocytic Lymphohistiocytosis Type 3 (FHL 3) is a rare genetic disorder that affects the immune system[1]. In this condition, the body’s immune cells don’t work properly, leading to severe inflammation and other health problems. FHL 3 is caused by mutations in a gene called UNC13D, which is important for the normal function of immune cells.

How MUNC-T3 Works

MUNC-T3 is a type of gene therapy that aims to correct the underlying genetic problem in FHL 3 patients[1]. Here’s a simplified explanation of how it works:

  1. The therapy uses the patient’s own cells, specifically a type of stem cell called CD34+ cells and T-cells (a type of immune cell).
  2. These cells are collected from the patient and modified in a laboratory to carry a correct version of the UNC13D gene.
  3. The modified cells are then given back to the patient through an intravenous (IV) infusion.
  4. The goal is for these modified cells to produce a normal version of the Munc13.4 protein (which is made by the UNC13D gene), helping to correct the immune system problem.

Treatment Process

The treatment involves two main components[1]:

  • MUNC-CD34: This is the modified stem cell component. Patients receive at least 2 million CD34+ cells per kilogram of body weight, with a maximum dose of 20 million cells per kilogram. These cells are given through an IV on day 0 of the treatment.
  • MUNC-T3: This is the modified T-cell component. Patients receive between 10,000 and 5 million T-cells per kilogram of body weight. These cells are given through an IV on day 14 after the initial treatment, and possibly again on day 28 if needed.

Potential Benefits

The researchers hope that MUNC-T3 therapy will offer several advantages over current treatments[1]:

  • Avoiding complications associated with donor stem cell transplants, such as graft-versus-host disease (where donor cells attack the patient’s body) and difficulties with engraftment (when donor cells fail to grow in the patient’s body).
  • Reducing the risk of severe side effects from the conditioning process (preparation for transplant).
  • Providing immediate support to fight infections, especially viral infections that often trigger FHL 3 symptoms.
  • Potentially improving overall survival and event-free survival (time without major health events) for patients.

Safety and Monitoring

As with any new treatment, safety is a top priority. The clinical trial is closely monitoring patients for any side effects or complications[1]. Some key safety measures include:

  • Monitoring for any treatment-related mortality up to 6 months after therapy.
  • Tracking the frequency and severity of side effects for up to 60 months (5 years).
  • Checking for any signs of abnormal cell growth or cancer development.
  • Testing for the presence of replication-competent lentivirus (the virus used to modify the cells) at regular intervals.

Ongoing Research

The clinical trial for MUNC-T3 is ongoing and will be collecting data on various aspects of the treatment[1], including:

  • How quickly patients’ blood cell counts recover after treatment.
  • The amount of corrected gene present in the patients’ cells over time.
  • The function of the patients’ immune cells after treatment.
  • The overall health outcomes for patients, including any need for intensive care and the occurrence of infections or other complications.

This research will help determine how effective MUNC-T3 is in treating FHL 3 and whether it could become a standard treatment option in the future.

Aspect Details
Study Type Phase I/II, Open Label, Non-Randomized, Monocentric, Single Arm
Condition Familial Hemophagocytic Lymphohistiocytosis Type 3 (FHL 3)
Intervention Gene therapy using modified autologous CD34+ cells (MUNC-CD34) and T-cells (MUNC-T3)
Primary Outcomes Transplant-related mortality, adverse events, malignancy incidence, detection of replication-competent lentivirus
Secondary Outcomes Blood cell recovery, gene integration, protein expression, immune cell function, complications, cost analysis
Follow-up Duration Up to 60 months post-treatment

FAQ

  • What is Munc-T3 and how is it used in this clinical trial? Munc-T3 is a modified T-cell product used in this gene therapy trial. It's administered intravenously to patients with FHL 3, typically 14 days after the main treatment with modified stem cells (MUNC-CD34). The goal is to provide immediately functional T-cells to help control infections while the patient's immune system recovers.
  • What is the primary goal of this clinical trial? The primary goal is to assess the safety and effectiveness of gene therapy for FHL 3 caused by mutations in the UNC13D gene. The study aims to replace traditional stem cell transplants with a method using the patient's own modified cells, potentially reducing complications and improving survival rates.
  • How long will patients be monitored in this trial? Patients will be monitored for up to 60 months (5 years) after treatment. Various assessments will be conducted throughout this period to evaluate the therapy's long-term effects and safety.
  • What are some of the key outcomes being measured in this trial? Key outcomes include the incidence of transplant-related mortality, frequency and severity of side effects, recovery of blood cell counts, the presence of the modified genes in blood cells, and the correction of immune cell function. The study will also monitor for any potential development of cancers related to the treatment.
  • Who is eligible for this clinical trial? The trial is designed for patients with Familial Hemophagocytic Lymphohistiocytosis Type 3 (FHL 3) caused by mutations in the UNC13D gene. It may be offered as an alternative to traditional stem cell transplants or as a backup option if previous transplants have failed.

Ongoing Clinical Trials on Munc-T3

  • Gene Therapy Study for Familial Hemophagocytic Lymphohistiocytosis Using MUNC-CD34 and MUNC-T3 in Patients with UNC13D Gene Mutations

    Not yet recruiting

    1 1
    Investigated diseases:
    Investigated drugs:
    France

Glossary

  • Familial Hemophagocytic Lymphohistiocytosis Type 3 (FHL 3): A rare genetic disorder affecting the immune system, characterized by uncontrolled activation of immune cells leading to inflammation and organ damage.
  • Gene Therapy: A technique that uses genes to treat or prevent disease, often by replacing a faulty gene or adding a new gene to help fight a disease.
  • Autologous Transplantation: A procedure where a person receives their own stem cells or tissues, which have been collected and stored beforehand.
  • CD34+ Cells: A type of stem cell found in bone marrow that can develop into different types of blood cells.
  • T-cells: A type of white blood cell that plays a central role in the body's immune response.
  • Graft versus Host Disease (GVHD): A complication that can occur after a stem cell or bone marrow transplant where the donor cells attack the recipient's body.
  • Veno-Occlusive Disease (VOD): A complication that can occur after stem cell transplants, causing blockage of small veins in the liver.
  • UNC13D Gene: A gene that provides instructions for making a protein involved in the release of toxic substances from certain immune cells.
  • Replication-Competent Lentivirus (RCL): A potential safety concern in gene therapy where the modified virus used to deliver genes could potentially replicate and spread.
  • Vector Copy Number (VCN): A measure of how many copies of the therapeutic gene have been inserted into the patient's cells.

References

  1. https://clinicaltrials.gov/study/NCT06736080